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ABSTRACT  
 
Dysferlin deficient muscular dystrophy is a devastating disease that leads to loss of 
mobility and quality of life in patients. Dysferlin is a 230 kD protein primarily expressed 
in skeletal muscle that functions in membrane resealing. Dysferlin loss of function leads 
to a decrease in the membrane resealing response after injury in skeletal muscle, which is 
thought to cause degeneration of the musculature over time.  
Dysferlin cDNA is 7.4 kb and exceeds AAV packaging capacity of ~ 5kb. This thesis 
focuses on the generation of mini dysferlin mutants that can be packaged in AAV for 
downstream testing of therapeutic efficacy. In addition, this thesis creates the 
groundwork for preclinical studies in mice that can potentially be translated to human 
patients. A mouse model for dysferlin deficiency was characterized and key disease 
phenotypes were identified. In addition, cell lines carrying a genetically encoded calcium 
indicator protein, gCaMP, were established to measure mini dysferlin resealing capacity 
and for downstream testing in vivo.
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CHAPTER I: INTRODUCTION TO DYSFERLIN DEFICIENT MUSCULAR 
DYSTROPHY  
Loss of function mutations in the dysferlin gene are the genetic defects found in 
patients with limb-girdle muscular dystrophy type 2B (LGMD2B), Miyoshi myopathy 
(MM), and distal myopathy with anterior tibial onset (DMAT) which, are autosomal 
recessive inherited disorders collectively termed “dysferlinopathies”. Dysferlin levels ≤ 
~20% in skeletal muscle lead to progressive muscular weakness, atrophy, and necrosis 
(1). Disease onset usually occurs when patients are in their late teens or early twenties, 
and at least one-third of patients are wheelchair-bound within 10 years of onset (1,2). The 
main difference between the three dysferlinopathy phenotypes is the muscle or muscle 
groups where disease onset occurs: pelvic and shoulder muscles in LGMD2B, 
gastrocnemius muscle in MM, and anterior tibialis muscle in DMAT (1,2). Over time, 
disease progression in additional muscle groups regardless of onset is inevitable, and can 
cause respiratory muscle weakness. Additionally, muscle biopsies from patients reveal 
variability in fiber sizes, increased connective tissue, necrosis, adipose accumulation, and 
centrally nucleated fibers (1,2).  
 
According to the Universal Mutation Database (www.umd.be/DYSF), there are 
416 pathogenic dysferlin mutations identified from 843 patients around the world to date. 
Most of these mutations are found in exons and as stated in the database, 33% are 
missense, 18% nonsense, 28% frameshift, 4% in-frame exonic insertions/deletions, and 
17% intronic mutations.  There is no particular “hot spot” for dysferlin mutations and
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no clear phenotype to genotype correlation has been established for each pathogenic 
mutation. Interestingly, there are cases where the same mutation in consanguineous 
individuals leads to two different phenotypes (3). A study by Liu & Brown in 1998 
identified dysferlin and described an Italian family where 3 out 5 siblings from 
unaffected parents developed dysferlinopathy. All three siblings (2 females and 1 male) 
had one allele carrying a 4265A>G mutation in exon 36 (I1298V) and the other allele 
carrying a 6497C>T mutation in exon 54 (R2042C)(3). The two daughters were affected 
by LGMD2B and the son was affected by MM. This strongly suggests that modifiers may 
influence the phenotype, however, none have been identified.  
 
 Dysferlin is a large 230 kD protein that is expressed primarily in mammalian 
skeletal muscle, but is also found in cardiac muscle, brain tissue, and monocytes (3,4,5). 
To date, 14 human transcript variants of dysferlin have been identified 
(www.umd.be/DYSF). Variant 8 (NCBI Reference Sequence: NM_003494.2) contains 
6,914 base pairs and encodes a 2088 amino acid protein that is the most commonly found 
variant in skeletal muscle. Dysferlin, or dystrophy-associated fer1-like protein, was 
named due to shared homology with C. elegans FER-1 protein (3). In C. elegans, FER-1 
has a direct role in vesicle fusion events during spermatogenesis (3,7). Otoferlin, 
myoferlin, and 3 uncharacterized fer1-like proteins (fer1L4,5,&6) share close homology 
with dysferlin in mammalian cells (8). Moreover, mutations in otoferlin are the cause of 
an autosomal recessive form of deafness (9,10).  
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Tandem C2 domains are a hallmark feature of ferlin family proteins (6,8). They 
are conserved sequences found in protein kinase C that bind Ca2+ and phospholipids 
(6,8,11). C2 domains have been well characterized in synaptotagmin, a Ca2+-sensor that 
participates in synaptic neurotransmitter release by triggering Ca2+-dependent exocytosis 
(11). Synaptotagmin I is a ~50 kD protein that contains two C2 domains C2A and C2B 
(6,11). The C2A domain has Ca2+ -binding loops composed of 5 aspartate residues and 
one serine residue that bind 3 Ca2+ ions (6,11). The structure of synaptotagmin C2 
domains is conserved among ferlin proteins (6). Biochemical studies in otoferlin 
demonstrate that C2 domains are calcium sensors, which bind SNARE proteins to 
mediate membrane fusion at the synapses of inner ear hair cells for neurotransmitter 
release (9,10). Dysferlin contains seven C2 domains A-G, which bind Ca2+ and 
phospholipids similarly to synaptotagmin (6), thus a function for dysferlin in calcium 
sensing and membrane fusion events is evident.  
 
In skeletal muscle fibers, dysferlin localizes to the sarcolemma (the plasma 
membrane of muscle cells) and is anchored by its C-terminal transmembrane domain, 
with the seven C2 domains located inside the cytoplasm (4,5,6). In 2003, two groups 
reported that dysferlin is directly involved in membrane resealing of sarcolemmal lesions 
(4,5). This observation was made after using two different techniques to wound the 
sarcolemma of a dysferlin null muscle cell. One group used a micropipette to carefully 
injure cultured myotubes and measured calcium influx by utilizing calcium indicator dye 
Indo1-AM (4). The other group employed a laser-mediated injury method in conjunction
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with lipophilic FM1-43 dye to measure resealing based on accumulation of the dye at the 
site of injury (5).  
Dysferlin was the first membrane repair protein identified in skeletal muscle. The 
membrane repair field arose in the last 20 years with the work of Richard Steinhardt and 
Paul McNeil. Steinhardt demonstrated that the mechanism for membrane resealing in sea 
urchin eggs and 3T3 fibroblasts is similar to neurotransmitter release (12). Microinjection 
of botulinum toxins that cleave SNAREs involved in the fusion step of neurotransmitter 
release inhibited membrane resealing in sea urchin eggs, thus suggesting Ca2+-dependent 
exocytosis was required (12). The following key observations leading to the now widely 
accepted “patch-hypothesis” for membrane resealing were: I.) vesicle accumulation at the 
site of membrane disruption reminiscent of docked vesicles during neurotransmitter 
release (15) and II.) The formation of an impermeant barrier after microinjection of 
[10mM] Ca2+ -containing seawater into the cytoplasm of a sea urchin egg (13,14). This 
barrier was confirmed to be a membrane by electron microscopy and staining with 
lipophilic dye (13,14). It was hypothesized that vesicle-vesicle fusion events led to its 
formation due to its unusually large size as visualized by EM (13,14). Interestingly, in the 
absence of Ca2+, significantly smaller vesicles accumulated at the site of injury and 
appear to be docked and unable to fuse (13,14). The patch hypothesis states that:  upon 
disruption, vesicle-vesicle and vesicle-plasma membrane fusions occur, resulting in 
accumulation of large vesicles at the injury site (17). Then, the patch is linked to the 
membrane via vesicle-plasma membrane fusion event (17). The identity of these vesicles 
is still debated; one group claims that lysosomes are exclusively utilized in the membrane 
repair pathway, due to localization of Lamp-1, a lysosome-specific protein at the lesion 
site while (16). Others including McNeil and Steinhardt contend that non-lysosomal 
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vesicles are also utilized for resealing based on the observations in sea urchin eggs (17). 
It is conceivable that recruited vesicle type may vary due to several factors such as injury 
size and/or cell type. Lennon and Brown in 2003 were the first to identify Lamp-1 on the 
sarcolemma of myotubes after injury in the presence of Ca2+(4). In addition, they 
reported a decrease in Lamp-1 expression at the sarcolemma after injury in cultured 
myotubes of dysferlin null mice (4). A recent study in coronary arterial endothelial cells 
shows that dysferlin promotes lysosome fusion to the plasma membrane via its C2A 
domain (19).  
The newest membrane repair associated protein identified, MG53, interacts with 
dysferlin at the C2A domain (20,21,22).  In the last few years, several studies have 
implicated annexins, caveolin-3, calpain-3, and MG53 in the dysferlin-mediated repair 
pathway; however, a clear mechanism has yet to emerge (20,21,22,23). A compelling 
new study by Lek et al 2013, demonstrates that rapid localization to the site of injury is 
exclusive to MG53 and dysferlin (24). In addition, the study shows that dysferlin is 
cleaved by calpain into a ~72 kD C-terminal fragment in a Ca2+ dependent manner after 
injury (24). This is particularly interesting because a naturally occurring 73 kD mini-
dysferlin containing the last two C2 domains near the C-terminus has been associated 
with a mild form of dysferlinopathy (23). The discovery of a mini-dysferlin by Krahn et 
al 2010, which retains the membrane resealing function led to the possibility of AAV-
mediated gene replacement therapy for Dysferlinopathy, because AAV does not have the 
packaging capacity for full-length dysferlin cDNA. 
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Adeno-associated viruses are small single-stranded DNA viruses that belong to the 
Parvoviridae family. The ~4.7kb ssDNA genome is enclosed in an icosahedral capsid 
that is comprised of three proteins: VP1, VP2, and VP3 in a 1:1:8 ratio (26,27). The 
capsid and replication genes are flanked by ITRs that form hairpin structures (26,27,28). 
In addition, genes encoding proteins required for replication and infection, Rep 78,68,52 
and 40, are found in the AAV genome (26,27).  Infection begins with AAV binding to the 
cell surface and entering the host cell through association with one or more host surface 
receptors or co-receptors depending on the AAV serotype (27).  The virus is then 
endocytosed, and undergoes a structural change in response to the acidic endosomal 
environment. This promotes escape from the endosome and the virus can then enter the 
nucleus and replicate its DNA (27). Once nuclear entry occurs, the ssDNA of the gene is 
converted to dsDNA by either, annealing of  + or – strands, or through host repair DNA 
polymerase (25). Wild-type AAVs are unable to replicate without additional “helpers” 
such as adenoviruses or herpesviruses, and in their absence, wild-type AAV integrates 
into the host genome and remains latent (26,27). In recombinant AAV vectors (rAAV), 
the wild-type ORF encompassing the replication and capsid genes is deleted and the 
rAAV vector genome contains only the transgene of interest flanked by ITRs (27). When 
rAAV dsDNA is produced in skeletal muscle, it is kept in a circular form where it can 
concatemerize and persist as an extrachromosomal element (25,29). rAAV does not 
encompass any wild-type AAV genes and cannot promote its own integration into the 
host genome. However, there is evidence that rAAV can integrate into the genome in the 
presence of host DNA double strand breaks in various tissues such as brain, skeletal 
muscle, heart, and liver (38). rAAV can also integrate by homologous recombination if 
the designed vector contains homologous sequences to the host genome (38).  
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AAV has never been associated with human disease, and due to its unique 
properties that allow for transgene vector engineering and viral transduction in a wide 
range of tissues, it has become a very promising vector for gene delivery.  
Two groups have exploited the biology of AAV in different ways to express full-
length dysferlin in skeletal muscle (29,30). One group utilized the concatemerization 
property of AAV to achieve full-length dysferlin expression via 2 independent vectors 
each carrying half of the protein (29). In this approach, the coding sequence was split 
between exons 28 and 29; one vector was packaged with the 5’ end of dysferlin cDNA 
that had an intron carrying a splice donor site, and the other vector contained the 3’ end 
with an intron carrying a splice acceptor site (29). Intramuscular injection of the dual 
vectors in dysferlin null mice achieved: expression in the muscle, restoration of 
membrane resealing, and histological improvement. Systemic injections also led to some 
histological improvements, however, according to their western blot analysis, only 1-4% 
dysferlin expression compared to WT levels was achieved (29). Therefore, these results 
imply that in humans, relying on the trans-splicing and concatemerization of dual vectors 
for transgene expression in the various muscle groups of the body following systemic 
injection may be ineffective.   
Another group sought to exploit the mechanism by which AAV5 mediates 
delivery of ~8kb genes (30). It was initially reported that this serotype had a large 
packaging capacity, however, studies have shown that this vector cannot package cDNA 
larger than 5kb (31). The mechanism by which large gene delivery occurs with
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rAAV5 is actually due to homologous recombination of partially packaged vectors 
(30,31). Intramuscular and regional vascular delivery of dysferlin via rAAV5 in dysferlin 
null mice also achieved functional and histological improvements (30). However, this 
mode of dysferlin delivery is probably not effective at achieving normal dysferlin 
expression in every muscle group of the body for patients receiving IV injections, since 
the homologous recombination frequency in mammalian cells is low. Furthermore, the 
ratio of partially packaged products delivered to every muscle group cannot be 
controlled, for example, if there is a higher ratio of either 5’ or 3’ product, this will affect 
how many particles can recombine to express full-length dysferlin. Because the 
feasibility of full-length dysferlin expression achieved in humans using AAV seems 
limited, the focus of my study is mini-dysferlin treatment for gene replacement therapy.  
We hypothesize that a partial dysferlin gene containing a set of domains critical for 
dysferlin function in skeletal muscle can reverse the dystrophic phenotype in dysferlin 
null mice and therefore, we will explore the therapeutic efficacy of various mini-dysferlin  
therapeutic candidates to overcome skeletal muscle degeneration associated with 
dysferlin loss of function.   
A recent report suggests a lack of correlation exists between rescue of membrane 
resealing function and histological improvement in dysferlin null mouse skeletal muscle 
following mini-dysferlin AAV treatment (32). The repair assay used in this study 
measured FM1-43 fluorescence uptake at the site of injury. The assumption that dye 
uptake directly correlates directly with membrane resealing may not be valid. It is 
possible that FM1-43 dye uptake at the site of injury does not directly measure resealing 
and therefore is not predictive of therapeutic outcome. One goal of this study is to 
develop tools for a downstream bioassay that directly measures membrane resealing to 
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assess mini-dysferlin AAV treatment in dysferlin null mice. It is now well established 
that membrane resealing is a calcium dependent process (12-17). We believe that 
measuring calcium influx in ex vivo muscle fibers is a more accurate measurement of the 
membrane resealing process in skeletal muscle cells. 
 
 In summary, the aims of this study are: to characterize the dystrophic phenotype 
in a new dysferlin null mouse strain, to develop mini dysferlin mutants to correct the 
dystrophic phenotype by AAV delivery, to develop gCaMP6s-Mini dysferlin cell lines to 
measure resealing function by calcium influx, and to further explore dysferlin biology by 
assessing mini dysferlin localization in dysferlin null muscle cells.  
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CHAPTER II: HISTOPATHOLOGICAL CHARACTERIZATION OF DYSFERLIN  
NULL BLA/J MOUSE STRAIN  
 
Introduction 
Various mouse models for dysferlin deficiency are now available (5,29,33). There are 
differences in age of onset, disease progression, dysferlin levels, and behavior among the 
mouse models. The SJL model contains a splice-site mutation in Exon 45 which causes 
an ~85% reduction in dysferlin levels, as confirmed by western blot and quantitative PCR 
(33). The A/J dysferlin deficient mouse model arose from continuous colony inbreeding 
at Jackson Laboratory and contains a retrotransposon insertion at the dysferlin locus  
(33). A/J mice display docile sedentary behavior and become overweight as they age, 
whereas, SJL mice are aggressive and must be housed separately from one another. SJL 
and A/J mice contain additional genetic defects aside from dysferlin deficiency due to 
decades of colony inbreeding and may not be ideal for therapeutic evaluation. The most 
recent dysferlin null model was created by backcrossing of the A/J strain with a wild-type 
C57BL6/J strain, resulting in a new strain termed Bla/J (29). These new Bla/J mice 
contain the A/J retrotransposon insertion at the dysferlin locus in a BL6(WT) 
background. Unlike A/J and SJL dysferlin null mice, Bla/J mice are active rather than 
sedentary and do not display aggressive behavior. The Bla/J strain is ideal for therapeutic 
evaluation with wild-type C57BL6/J controls. This new model has not been extensively 
characterized. 
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Results  
 
Gross Anatomy and Histology of Bla/J Musculature 
 
Bla/J mice live up to  ~18-20 months of age until euthanization is required due to weight 
loss and gait irregularities. At this end stage, most hindlimb and forelimb muscle groups 
have degenerated, with the quadriceps and triceps being the most affected (Figure 1A & 
B). Gross anatomical examination of the hindlimb musculature at 18 months of age 
(Figure 1A) reveals more advanced degeneration in the quadriceps than in the 
gastrocnemius or tibialis anterior muscles of dysf -/- Bla/J mice (n=6) when compared to 
healthy dysf  +/- age-matched littermate controls (n=4).  
 
H&E staining of 18 month-old Bla/J muscle cross-sections reveal key hallmark features 
of muscle disease pathology such as fiber shape irregularity, centrally nucleated fibers, 
macrophage infiltration, fibrosis, and adipose deposits (Figure 1B). Both triceps (Figure 
1B, panel A) and quadriceps (Figure 1B, panel B) sections display severe immune cell 
infiltration around the vasculature and substantial amount of adipose accumulation (n=6). 
The gastrocnemius and tibialis anterior (Figure 1B, panels C & D) muscle groups appear 
only mildly affected relative to the triceps and quadriceps, but still contain the presence 
of centrally nucleated fibers. 
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Figure 1A: Gross Anatomy of 18 month-old WT vs. Bla/J hindlimb musculature.  
Figure 1B: Bla/J H&E Histology A. Diseased triceps presenting macrophage infiltration 
(purple mass at image center) and adipose accumulation (white circular patterns) B. 
quadriceps presenting macrophage infiltration, adipose accumulation, fiber shape 
irregularity, and centrally nucleated fibers. C. Gastrocnemius section displaying presence 
of centrally nucleated fibers. D.4x image of Tibialis Anterior shows the entirety of this 
muscle is only mildly affected.  
 
 
	   	   13	  	  
 
 
Membrane Integrity of Bla/J Muscle  
Evans blue dye is an azo dye that binds to serum albumin and is not present inside muscle 
fibers of healthy wild-type mice and dye uptake into skeletal muscle fibers suggests a 
diseased state of the fiber where sarcolemmal integrity is compromised (43).   
Intraperitoneal injections of Evans blue dye were administered to eight-month old dysf -/- 
Bla/J and wild-type C57BL6/J and tissue was harvested 16 hours post injection (Figure 2 
A & B). Upon gross anatomical examination, Evans blue dye is observed to penetrate the 
skeletal musculature of dysferlin deficient mice, giving them an overall blue appearance 
(Figure 2A). Because Evans blue emits fluorescence in the red channel, evaluation of dye 
penetration inside skeletal muscle fibers is viable. Evaluation of dye uptake in various 
muscle groups in 8 month-old dysf -/- mice reveals that the gastrocnemius and quadriceps 
have the most dye uptake, which also correlates with more severe histopathology of these 
two muscle groups as observed by H&E staining at this particular time point (Figure 2B, 
rows A & B). The next goal was to identify the earliest time point of dye uptake in dysf   
-/- skeletal muscle. Evans blue dye intraperitoneal injections where administered to 
5,6,and 7 month-old dysf -/- Bla/J mice and dye penetration into muscle fibers was 
evaluated by fluorescence microscopy (Figure 3A). Significant uptake into the 
gastrocnemius and quadriceps is observed starting at 7 months of age, also correlating 
with the histopathological deterioration of the muscle as seen on the H&E stains. 
Deterioration appears more pronounced in the quadriceps than in the gastrocnemius and 
dye uptake area in the quadriceps appears greater at this time point. Interestingly, when 
Evans blue dye was administered to end stage 20 month-old dysf -/- Bla/J mice with 
severe histopathology, only a small amount of dye uptake was observed (Figure 3B).  
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Figure 2A: Gross anatomical evaluation of Evans blue dye uptake into the musculature of 
dysf -/- and WT mice post injection.  
Figure 2B: Histological evaluation of Evans blue dye uptake into muscle fibers of 
different muscle groups (left panel) and H&E staining (right panel).  
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Figure 3A: Evans blue dye uptake into dysf -/- Bla/J gastrocnemius and quadriceps 
muscles at 5,6,and 7 months of age and H&E stains of disease progression (bottom 
panel). 
Figure 3B: Evans blue dye uptake into tibialis anterior, gastrocnemius, quadriceps, and 
triceps of 20 month old dysf -/- Bla/J mice and H&E stains of each muscle group (bottom 
panel.) 
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Materials and Methods 
Mice  
All experiments involving mice were approved by the UMass Medical School IACUC.  
Dysf -/- Bla/J mice and C57BL6/J mice were purchased from Jackson Laboratory and 
housed in accordance with our IACUC protocol and institutional standards.  
Histology 
Tissue extracted from mice upon dissection was either fixed in 10% neutral buffered 
formalin (Sigma cat# HT501128) for 24 hours followed by paraffin embedding and 
sectioning at 4 um using a Leica microtome (Figure 1B) or fresh-frozen in liquid 
nitrogen-cooled isopentane (Sigma cat#M32631-4L) and sectioned in OCT medium 
(Electron Microscopy Sciences cat#62550-12) at 10 um on a Leica cryostat (Figures 
2&3). Paraffin embedded sections were deparaffinized with xylene (Sigma cat# 534056-
4L) washes and rehydrated in a 100%-70% ethanol gradient for H&E staining. Fresh–
frozen sections were washed in 1X PBS (Fisher cat# BP3994) for 5 minutes and stained 
with hematoxylin (Leica cat#3801562) for 5 minutes, rinsed with tap water, and stained 
with Eosin (Leica cat#3801602) for two minutes followed by dehydration through a 70%-
100% ethanol gradient, followed by two 5 minute xylene washes. Sections were mounted 
in DPX (Sigma cat# 06522) mounting medium.  Images were acquired with a Nikon Ti 
microscope. 
Evans Blue Dye Injections 
Evans blue powder (Sigma cat# E2129) was dissolved in 1X PBS at [0.01 mg/uL] and 
filter sterilized through a 0.22 um Millipore filter. Mice were injected with 100 uL of 
Evans blue dye in 1X PBS solution per 10 grams of body weight and euthanized 16 hours 
post injection. Tissue was harvested and fresh-frozen as described above.
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CHAPTER III: GENERATION OF MINI DYSFERLIN gCAMP6 EXPRESSING 
CELL LINES FOR DOWNSTREAM MEMBRANE RESEALING ASSAY AND 
DEVELOPMENT OF MINI DYSFERLIN DELETION MUTANTS FOR GENE 
THERAPY 
Introduction 
As mentioned previously in the main introduction of this thesis, the discovery of a 
mini-dysferlin by Krahn et al 2010, which retains the membrane resealing function led to
the possibility of mini dysferlin gene replacement therapy for Dysferlinopathy, due to 
limited AAV packaging capacity for full-length dysferlin cDNA. However, a recent 
report suggests a lack of correlation exists between rescue of membrane resealing 
function and histological improvement in dysferlin null mouse skeletal muscle following 
mini-dysferlin AAV treatment (32). The repair assay used in this study measured FM1-43 
fluorescence uptake at the site of injury. The assumption that dye uptake directly 
correlates with membrane resealing may not be valid. It is possible that FM1-43 dye 
uptake at the site of injury does not directly measure resealing and therefore is not 
predictive of therapeutic outcome. One goal of this study is to develop tools for a 
downstream bioassay that directly measures membrane resealing by calcium influx to 
assess mini-dysferlin AAV treatment in dysferlin -/- Bla/J mice that were characterized.  
The final goal of this study is to create mini dysferlin deletion mutations packaged into 
AAV and to validate expression in vivo using the Bla/J dysferlin null mouse model 
characterized.  
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Results 
Development of gCaMP6s-expressing Dysferlin -/-  Patient Myoblast Cell Lines   
The gCaMP family of genetically encoded calcium indicator proteins are now widely 
used to measure calcium transients (34,35,36,37). The gCaMP protein is a fusion between 
circularly permutated GFP, calmodulin calcium binding domain, and M13 synthetic 
peptide(34,35,36,37).In the presence of calcium, a conformational change occurs in 
gCaMP, which causes the emission of GFP fluorescence. These unique properties of 
gCaMP were exploited for in vitro imaging of calcium transients in differentiated skeletal 
muscle cells after the cells were transduced with lentivirus carrying gCaMP6s, the latest, 
most sensitive, version of the gCaMP proteins.  In Figure 4A, gCaMP6s fluorescence is 
observed 5 seconds post razor blade scratch injury to the cell.  After 5 minutes post 
injury, the gCaMP6s signal returns to baseline in the part of the cell that did not detach 
from the plate post scratch injury. This simple proof-of-concept experiment confirms that 
gCaMP6s can be utilized to measure calcium transients in skeletal muscle. gCaMP6s was 
then introduced to dysferlin null patient myoblast 379 line through lentivirus infection 
(Figure 4B). Dysferlin deletion mutants were then introduced to the gCaMP6s-dysferlin 
null 379 cell line (Figures 4C & 4D). Five gCaMP6s-mini dysferlin expressing cell lines 
were created to test the membrane resealing capacity of each mini dysferlin deletion 
mutant using gCaMP6s as a reporter of calcium influx after sarcolemmal injury.  
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Figure 4A: gCaMP6s fluorescence transient in a WT C25 human myoblast differentiated 
cell line. The white broken line in the middle panel denotes the razor scratch injury 
trajectory. The yellow box denotes a region in the myofiber where it is intact from razor 
damage where the calcium transient after injury can be observed.   
Figure 4B:  A western blot confirming dysferlin expression in WT C25 myoblasts and 
confirming dysferlin loss in dysferlin null 379 myoblasts from differentiation day 0-4.  
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Figure 4C: Western blot confirming mini dysferlin deletion mutant expression in 
gCaMP6s  dysferlin null cell line 379, after lentivirus transduction of each mini dysferlin.  
Figure 2D: Map of dysferlin domains present in each mini dysferlin deletion mutant.  
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Mini Dysferlin Localization in gCaMP6s-dysferlin Null 379 Cell Line  
After introducing each mini dysferlin to gCaMP6s-dysferlin null 379 cell line, five 
separate cell lines were created and mini dysferlin localization was assessed in each.  
When cell lines were probed with dysferlin antibody NCL-Hamlet, which recognizes the 
C-terminus of WT dysferlin (present in all deletion mutants), a punctate staining pattern 
appeared for all deletion mutants (Figure 5A). The mini dysferlins do not seem to be 
present in the membrane, in contrast to WT dysferlin and dystrophin staining (Figure 
5A). However, a different staining pattern emerges when some mini dysferlin cell lines 
were probed with NCL-Romeo, a dysferlin antibody that recognizes the N-terminus ( 
Figure 5B). The staining pattern of the mini dysferlin cell lines probed with Romeo 
resemble WT dysferlin cell line staining and dystrophin staining shown in (Figure 5A). 
This difference suggests that dysferlin may be cleaved and only a part of the truncated 
protein localizes to the membrane.  
AAV9-mediated Mini Dysferlin Delivery to Dysferlin -/- Bla/J Mice Skeletal Muscles 
Mini dysferlin mutants were cloned into AAV vectors and packaged into AAV9 serotype.  
Bilateral intramuscular injections were carried out at 1.5x1011 vector genomes dosage in 
the quadriceps and gastrocnemius muscles of dysferlin null Bla/J mice (n=3 per mini 
dysferlin). Tissue was harvested 3 weeks post injection. Surprisingly, no transgene 
expression was observed by western blot (Figure 6) or immunostaining muscle 
sections(data not shown). The experiment was repeated with two more cohorts of mice 
including n=3 for each mini dysferlin and no transgene expression was observed. 
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Figure 5A: Mini dysferlin punctate staining pattern in myotubes when probed with NCL-
Hamlet. 
Figure 5B: Comparison of mini dysferlin staining patterns when probed with C-terminus 
and N-terminus recognizing antibodies.  
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Figure 6: Western blot showing no mini dysferlin expression in mouse gastrocnemius and 
quadriceps muscles injected with AAV9 carrying mini dysferlin constructs.  
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Materials and Methods  
 
Cloning  
 
CMV- gCaMP6s sequence was amplified from pGP-CMV-GCaMP6s vector (Addgene 
#40753) with forward primer   5'-TTCGGGACCCATAGTAATCAATTACGGGGTCAT 
- 3' incorporating a PpuMI restriction site and reverse primer 5’-TGGGAATTCTCACTT 
CGCTGTC-3’ containing an EcoRI restriction site. The 1.9 kb amplicon was amplified 
using Phusion High Fidelity DNA Polymerase (NEB #M0530S) and digested with 
PpuMI and EcoRI restriction endonucleases (NEB #R0506S, #R3101S ) and column 
purified. pLKO.1hygro vector ( Addgene ##24150)  was also digested with PPuMI and 
EcoRI restriction ezymes and a 7 kb backbone was extracted from an agarose gel after 
electrophoresis.  Amplified CMV-gCaMP6s fragment was ligated with pLKO.1 hygro 
vector at a 3:1 insert:vector ratio using  T4 DNA ligase ( NEB #M0202S). The plasmid 
was transformed into Stbl3 competent E. coli cells (Invitrogen #C737303). After 
propagation and purification from Stbl3 cells, pLKO.1hygro-CMV-gCaMP6s was 
sequenced. 
Mini Dysferlins were cloned from full-length dysferlin cDNA into lentivirus vector 
CSCW2-IRES-mcherry using forward primer 5’-aaaaggtctcGCTAGCGCCACCATGCT 
GAGGGTC-3’ with NheI restriction site and reverse primer 5’- aaaaggtctcCTCGAGTC 
AGCTGAAGGGCTTCACC-3’ with XhoI restriction site (NEB# R0131S, R0146S). 
Amplified mini dysferlins  and CSCW2-IRES-mcherry vector were digested with NheI 
and XhoI restriction enzymes and fragments were extracted from agarose gel based on 
size. Each mini dysferlin was ligated with the vector backbone at 3:1 ratio using T4 DNA 
ligase. Plasmids were transformed into Stbl3 cells, propagated, purified, and sequenced. 
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Mini dysferlin sequences were cloned out of lentivirus vectors and into a pAAV vector 
backbone with the NheI and XhoI restriction sites for AAV packaging. After ligation 
with T4 DNA ligase, plasmids were transformed into SURE2 competent cells (Agilent #	  
200152), propagated, and sequenced.  
 
Lentivirus Production and Cell Line Generation  
pLKO.1hygro-CMV-gCaMP6s and all CSCW2-CMV-Mini Dysferlin-IRES-mcherry 
constructs were packaged into lentivirus using the most recent protocol adapted from  
Molecular Cloning 4th edition volume 2. gCaMP6s expressing cells were created by 
lentivirus infection of pLKO.1hygro-CMV-gCaMP6s into dysferlin null patient cells 
(379) and WT control ( C25) and both cell lines were subjected to hygromycin selection. 
After selection, 379-gcamp6s cells were infected with lentivirus packaged with dysferlin 
deletion mutants (CSCW2-CMV-minidysf-IRES-mcherry).  Mcherry positive cells were 
FACS sorted. Myoblasts were cultured in 0.1% gelatin coated dishes with Promocell 
SGM proliferation medium, 20% FBS. Myoblasts were differentiated with Promocell 
Skeletal Muscle Differentiation medium. Immortalized human cell lines C25 and 379 
were a gift from Vincent Mouly. 
Western Blotting 
Cell culture lysates were sonicated for 20 seconds and 20% amplitude in RIPA buffer. 
Tissue lysates were prepared by homogenization in T-PER buffer with a dounce 
homogenizer. BCA assays were used to determine protein concentration as per kit 
intstructions. Lysates were added to 2X Laemli buffer and boiled for 10 minutes at 70C. 
Boiled samples were then loaded to Bio-Rad precast gradient gels for electrophoresis. 
Proteins were transferred to nitrocellulose membranes using Invitrogen iBlot system and 
probed with anti-dysferlin antibody NCL-Hamlet. 
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Immunostaining  
Mini dysferlin-expressing and control myoblasts were cultured in gelatin coated MatTek 
( #	  P35G-1.0-20-C) and differentiated until day 4. On Day 4, cells were rinsed with 1X 
PBS, incubated with acetone for 5 minutes , rinsed again with 1X PBS, and blocked for 
45 minutes with 10% goat serum.Cells were then incubated with primary antibody ( 
NCL-Hamlet or Romeo) for 1 hour, rinsed 3 times with 1X PBS, and incubated for 45 
minutes with secondary anti-mouse or anti-rabbit antibody conjugated to Molecular 
Probes Alexa-Fluor 690. Plates were imaged using Nikon Ti Fluorescent microscope.  
 
AAV9 Mini dysferlin delivery  
Two milligrams of mini dysferlin cDNA in pAAV backbone were purified using Qiagen 
Endotoxin free Mega-Prep kit  (#12381) and submitted to the UMass Medical School 
Gene Therapy Core Facility for packaging into AAV9.  
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CHAPTER IV: DISCUSSION 
This thesis lays down the groundwork for a pre-clinical study in dysferlin null 
Bla/J mice to assess mini dysferlin therapeutic efficacy for dysferlin deficient muscular 
dystrophy gene therapy. This study has identified the muscle groups in the dysferlin null 
Bla/J mouse model with the most severe histological phenotype (triceps and quadriceps) 
and most severe loss of membrane integrity phenotype (gastrocnemius and quadriceps).  
The severe histological phenotype observed in both quadriceps and triceps at 18 months 
could be due to the utilization of these muscles by the mice to support their body weight. 
The quadriceps seem to be the muscle group most widely utilized for both support of 
body weight and locomotion, thus it displays accelerated disease progression in 
comparison to the other groups characterized. These results suggest that the quadriceps is 
the ideal muscle group for phenotype evaluation after therapeutic intervention since it 
displays the most severe histological phenotype and loss of membrane integrity. Loss of 
membrane integrity appearing in the gastrocnemius without the same degree of 
histological severity as the quadriceps or triceps could be due to its primary function, 
which involves running and jumping that constantly stress the muscle fibers making them 
more permeable.  The results from this study suggest that disease progression varies 
among muscle groups, and this may be explained by muscle function, physiology, and 
utilization by the mice.   
This study characterized disease onset, progression, and endpoint in the Bla/J mouse. 
Taken together, this phenotype and disease progression characterization will be critical 
for establishing start points and endpoints of a pre-clinical study in these mice to assess a 
potential reversal of the dystrophic phenotype mediated by a mini dysferlin construct 
with therapeutic efficacy. 
 This study has also laid down the groundwork for elucidating dysferlin 
membrane resealing function and C2 domain function. gCaMP6s-mini dysferlin 
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expressing cell lines can be utilized for a more advanced membrane resealing assay using 
a laser-induced focal injury to the membrane to evaluate mini dysferlin resealing capacity 
measured directly by calcium influx.  These future studies will shed light on the dysferlin 
membrane resealing function controversy in the field. Results from mini dysferlin 
localization studies with different staining patterns observed with two different anti 
dysferlin antibodies suggest that the protein may be cleaved and this cleavage might 
affect localization. A study in 2013 by Lek et al, showed compelling evidence that 
dysferlin is cleaved at the C-terminus after injury to the membrane. When the site of 
injury was probed with 3 different anti-dysferlin antibodies (one against the C-terminus 
and two against the N-terminus), only C-terminus dysferlin co-localized with the injury 
site. Furthermore, western blot analysis of injured myotubes showed the presence of a 
small 72 kD C-terminus dysferlin fragment that was absent in uninjured controls.   
Further co-localization studies can be performed with the mini dysferlin cell lines 
described in this thesis to uncover dysferlin protein biology and its role in membrane 
resealing.  
It is imperative that mini dysferlin constructs in AAV vectors created are further 
improved by altering the promoter and AAV serotype to confirm robust transgene 
expression in vivo and assess therapeutic efficacy. In all, this thesis has uncovered the 
dystrophic disease progression in a mouse model mimicking the human disease in 
addition to constructing important elements for downstream pre-clinical and biological 
studies that will surely contribute to the Dysferlin field.   
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